{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:23:47Z","timestamp":1754108627984},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,9,29]],"date-time":"2013-09-29T00:00:00Z","timestamp":1380412800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00520-013-1973-6","type":"journal-article","created":{"date-parts":[[2013,9,28]],"date-time":"2013-09-28T07:34:11Z","timestamp":1380353651000},"page":"325-330","source":"Crossref","is-referenced-by-count":8,"title":["Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?"],"prefix":"10.1007","volume":"22","author":[{"given":"Bruce","family":"Charles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Tapuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rani","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Norris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,29]]},"reference":[{"key":"1973_CR1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00520-002-0385-9","volume":"11","author":"MP Davis","year":"2003","unstructured":"Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R (2003) Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 11:84\u201389","journal-title":"Support Care Cancer"},{"key":"1973_CR2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12094-007-0057-9","volume":"9","author":"A Ordonez Gallego","year":"2007","unstructured":"Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E (2007) Oxycodone: a pharmacological and clinical review. Clin Transl Oncol 9:298\u2013307","journal-title":"Clin Transl Oncol"},{"key":"1973_CR3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1185\/030079908X253708","volume":"24","author":"J Riley","year":"2008","unstructured":"Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L (2008) Oxycodone: a review of its use in the management of pain. Curr Med Res Opin 24:175\u2013192","journal-title":"Curr Med Res Opin"},{"key":"1973_CR4","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/0269216311401948","volume":"25","author":"SJ King","year":"2011","unstructured":"King SJ, Reid C, Forbes K, Hanks G (2011) A systematic review of oxycodone in the management of cancer pain. Palliat Med 25:454\u2013470","journal-title":"Palliat Med"},{"key":"1973_CR5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.12968\/ijpn.2001.7.11.9291","volume":"7","author":"R Cairns","year":"2011","unstructured":"Cairns R (2011) The use of oxycodone in cancer-related pain: a literature review. Int J Palliat Nurs 7:522\u2013527","journal-title":"Int J Palliat Nurs"},{"key":"1973_CR6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","volume":"79","author":"B Lalovic","year":"2006","unstructured":"Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen L-Y, Shen DD (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating metabolites. Clin Pharmacol Ther 79:461\u2013479","journal-title":"Clin Pharmacol Ther"},{"key":"1973_CR7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0009-9236(98)90051-0","volume":"64","author":"T Heiskanen","year":"1998","unstructured":"Heiskanen T, Olkkola KT, Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64:603\u2013611","journal-title":"Clin Pharmacol Ther"},{"key":"1973_CR8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1445-5994.2009.01982.x","volume":"39","author":"M Leong","year":"2009","unstructured":"Leong M, Murnion B, Haber PS (2009) Examination of opioid prescribing in Australia from 1992 to 2007. Int Med Journal 39:676\u2013681","journal-title":"Int Med Journal"},{"key":"1973_CR9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0952-8180(95)00092-5","volume":"8","author":"M Kirvela","year":"1996","unstructured":"Kirvela M, Lindgren L, Seppala T, Olkkola K (1996) The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 8:13\u201318","journal-title":"J Clin Anesth"},{"key":"1973_CR10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0009-9236(97)90100-4","volume":"61","author":"M Tallgren","year":"1997","unstructured":"Tallgren M, Olkkola KT, Seppala T, Hockerstedt K, Lindgren L (1997) Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 61:655\u2013661","journal-title":"Clin Pharmacol Ther"},{"key":"1973_CR11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/bja\/aer395","volume":"108","author":"TI Saari","year":"2012","unstructured":"Saari TI, Ihmsen H, Neuvonen PJ, Olkkola KT, Schwilden H (2012) Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Brit J Anaesth 108:491\u2013498","journal-title":"Brit J Anaesth"},{"key":"1973_CR12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00228-010-0948-5","volume":"67","author":"TN Andreassen","year":"2011","unstructured":"Andreassen TN, Klepstad P, Davies A, Bjordal K, Lundstr\u00f6m S, Kaasa S, Dale O (2011) Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol 67:493\u2013506","journal-title":"Eur J Clin Pharmacol"},{"key":"1973_CR13","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1345\/aph.1D374","volume":"38","author":"EI Ette","year":"2004","unstructured":"Ette EI, Williams PJ (2004) Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 38:1702\u20131706","journal-title":"Ann Pharmacother"},{"key":"1973_CR14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00520-011-1147-3","volume":"20","author":"J Hardy","year":"2012","unstructured":"Hardy J, Norris R, Anderson H, O'Shea A, Charles B (2012) Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer? Support Care Cancer 20:767\u2013772","journal-title":"Support Care Cancer"},{"key":"1973_CR15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jchromb.2006.10.039","volume":"848","author":"SR Edwards","year":"2007","unstructured":"Edwards SR, Smith MT (2007) Low level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. J Chromatogr B 848:264\u2013270","journal-title":"J Chromatogr B"},{"key":"1973_CR16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/0091270008314465","volume":"48","author":"C Staahl","year":"2008","unstructured":"Staahl C, Upton R, Foster DJR, Christrup LL, Kristensen K, Hansen SH, Arendt-Nielsen L, Drewes AM (2008) Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model. J Clin Pharmacol 48:619\u2013631","journal-title":"J Clin Pharmacol"},{"key":"1973_CR17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-200241050-00002","volume":"41","author":"B Meibohm","year":"2002","unstructured":"Meibohm B, Beierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41:329\u2013342","journal-title":"Clin Pharmacokinet"},{"key":"1973_CR18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/JCP.0b013e3182189892","volume":"31","author":"A Liukas","year":"2011","unstructured":"Liukas A, Hagelberg NM, Kuusniemi K, Neuvonen PJ, Olkkola KT (2011) Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. J Clin Psychopharmacol 31:302\u2013308","journal-title":"J Clin Psychopharmacol"},{"key":"1973_CR19","first-page":"961","volume":"3","author":"HH Villesen","year":"2007","unstructured":"Villesen HH, Banning A-M, Petersen RH, Weinelt S, Poulsen JB, Hansen SH, Christrup LL (2007) Pharmacokinetic s of morphine and oxycodone following intravenous administration in elderly patients. Ther Clin Risk Manage 3:961\u2013967","journal-title":"Ther Clin Risk Manage"},{"key":"1973_CR20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0009-9236(96)90024-7","volume":"59","author":"RF Kaiko","year":"1996","unstructured":"Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD (1996) Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 59:52\u201361","journal-title":"Clin Pharmacol Ther"},{"key":"1973_CR21","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jpain.2009.03.017","volume":"10","author":"M Cherrier","year":"2009","unstructured":"Cherrier M, Amory JK, Ersek M, Risler L, Shen D (2009) Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults. J Pain 10:1038\u20131050","journal-title":"J Pain"},{"key":"1973_CR22","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00228-012-1267-9","volume":"68","author":"M Kokki","year":"2012","unstructured":"Kokki M, V\u00e4litalo P, Rasanen I, Aaltomaa S, Ojanper\u00e4, Eskelinen M, Kokki H (2012) Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. Eur J Clin Pharmacol 68:1357\u20131363","journal-title":"Eur J Clin Pharmacol"},{"key":"1973_CR23","doi-asserted-by":"crossref","first-page":"A62","DOI":"10.1136\/bmjspcare-2012-000196.182","volume":"2","author":"R Ackroyd","year":"2012","unstructured":"Ackroyd R, Aman S (2012) Use of oxycodone and association with renal function. BMJ Support Palliat Care 2:A62\u2013A63","journal-title":"BMJ Support Palliat Care"},{"key":"1973_CR24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3109\/15360288.2012.702200","volume":"26","author":"T Komatsu","year":"2012","unstructured":"Komatsu T, Kokubun H, Suzuki A, Takayanagi R, Yamada Y, Matoba M, Yago K (2012) Population pharmacokinetics of oxycodone in patients with cancer-related pain. J Pain Palliat Care Pharmacother 26:220\u2013225","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"1973_CR25","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00228-012-1266-x","volume":"68","author":"T Naito","year":"2012","unstructured":"Naito T, Tashiro M, Yamamoto K, Ohnishi K, Kagawa Y, Kawakami J (2012) Impact of cachexia on pharmacokinetic disposition of and clinical response to oxycodone in cancer patients. Eur J Clin Pharmacol 68:1411\u20131418","journal-title":"Eur J Clin Pharmacol"},{"key":"1973_CR26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1503\/cmaj.1040752","volume":"172","author":"EG Giannini","year":"2005","unstructured":"Giannini EG, Testa R, Savarino V (2005) Liver enzyme alteration: a guide for clinicians. CMAJ 172:367\u2013379","journal-title":"CMAJ"},{"key":"1973_CR27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/clpt.2008.262","volume":"85","author":"JR Senior","year":"2009","unstructured":"Senior JR (2009) Monitoring for hepatotoxicity: what is the predictive value of liver \u201cfunction\u201d tests? Clin Pharmacol Ther 85:331\u2013334","journal-title":"Clin Pharmacol Ther"},{"key":"1973_CR28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2165\/00003088-199529050-00005","volume":"9","author":"DJ Morgan","year":"1995","unstructured":"Morgan DJ, McLean AJ (1995) Clinical pharmacokinetics and pharmacodynamic considerations in patients with liver disease\u2014an update. Clin Pharmacokinet 9:370\u2013391","journal-title":"Clin Pharmacokinet"},{"key":"1973_CR29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF02353475","volume":"24","author":"GR Wilkinson","year":"1996","unstructured":"Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475\u2013490","journal-title":"J Pharmacokinet Biopharm"},{"key":"1973_CR30","first-page":"46","volume":"5","author":"J Hardy","year":"1998","unstructured":"Hardy J (1998) Corticosteroids in palliative care. Eur J Pall Care 5:46\u201350","journal-title":"Eur J Pall Care"},{"key":"1973_CR31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0885-3924(96)00300-4","volume":"13","author":"DP Benziger","year":"1997","unstructured":"Benziger DP, Miotto J, Grandy RP, Thomas GB, Swanton RE, Fitzmartin RD (1997) A pharmacokinetic\/pharmacodynamic study of controlled-release oxycodone. J Pain Symptom Manage 13:75\u201382","journal-title":"J Pain Symptom Manage"},{"key":"1973_CR32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1046\/j.1365-2125.1996.00481.x","volume":"42","author":"JW Mandema","year":"1996","unstructured":"Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR (1996) Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 42:747\u2013756","journal-title":"Br J Clin Pharmacol"},{"key":"1973_CR33","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/jat\/27.6.346","volume":"27","author":"KA Moore","year":"2003","unstructured":"Moore KA, Ramcharitar V, Levine B, Fowler D (2003) Tentative identification of novel oxycodone metabolites in human urine. J Anal Toxicol 27:346\u2013352","journal-title":"J Anal Toxicol"},{"key":"1973_CR34","first-page":"460","volume":"47","author":"M Mouelhi El","year":"1987","unstructured":"El Mouelhi M, Didolkar MS, Elias EG, Guengerich FP, Kauffman FC (1987) Hepatic drug-metabolizing enzymes in primary and secondary tumors of human liver. Cancer Res 47:460\u2013466","journal-title":"Cancer Res"},{"key":"1973_CR35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jpainsymman.2011.05.008","volume":"43","author":"T Andreassen","year":"2012","unstructured":"Andreassen T, Klepstad P, Davies A, Bjordal K, Lundstr\u00f6m S, Kaasa S, Dale O (2012) Is oxycodone efficacy reflected in serum concentrations? A multicenter, cross-sectional study in 456 adult cancer patients. J Pain Symptom Manag 43:694\u2013705","journal-title":"J Pain Symptom Manag"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1973-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-013-1973-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1973-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T01:03:49Z","timestamp":1596589429000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-013-1973-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,29]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["1973"],"URL":"https:\/\/doi.org\/10.1007\/s00520-013-1973-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,29]]}}}